The US FDA has granted approval
to Ninlaro (ixazomib), made by
Takeda, which is the “first and
only oral proteasome inhibitor”
indicated in combination with
lenalidomide and dexamethasone
for the treatment of patients with
multiple myeloma.
Ninlaro is administered as a once weekly
tablet, with the coming just
months after Takeda submitted its
new drug application to the FDA in
Jul and subsequently being granted
Priority review status “reflecting
the profound and continuing unmet
need for new treatments”.The above article was sent to subscribers in Pharmacy Daily's issue from 25 Nov 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 Nov 15
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.